Vasculitis UK has granted £53,364 (about $73,500) to support a research project investigating how people with ANCA-associated vasculitis (AAV) and other vasculitis respond to COVID-19 vaccines. Led by Lucy Fairclough, PhD, an associate professor at Nottingham University, in the U.K., the project seeks to…
Vasculitis UK Funds COVID-19 Vaccine Study
A committee of the U.S. Food and Drug Administration (FDA) is holding a public meeting to discuss the potential approval of avacopan for the treatment of ANCA-associated vasculitis (AAV). During the meeting of the FDA’s Arthritis Advisory Committee, members will review safety and efficacy data of Chemocentryx’s…
In patients with systemic vasculitis like ANCA-associated vasculitis (AAV), glucocorticoid use and respiratory disease are linked with severe COVID-19 outcomes, a recent study reports. “Together with reports of other cohorts exposed to immunosuppressant medication, these data could inform future public health guidance for individuals…
The Childhood Arthritis and Rheumatology Research Alliance (CARRA) has established alternative consensus treatment plans for children and adolescents with severe ANCA-associated vasculitis (AAV). These plans, which compare two therapies for induction and maintenance of remission in pediatric…
What is your diagnosis day? Mine is April 1, 2007. There was irony in finding out I had a life-altering, incurable illness on April Fools’ Day. I accused my doctor of playing a prank on me. I thought he was joking. Before my diagnosis, a few medical professionals…
As anyone affected by a rare disease knows, treating the illness while trying to go about everyday life is an expensive undertaking. But exactly how expensive — in terms of direct and indirect costs across rare disease populations — might still come as a surprise: almost…
People with ANCA-associated vasculitis (AAV) who receive mycophenolate mofetil (MMF) as a remission induction therapy have similar remission rates as those given cyclophosphamide (CYC), an analysis of eight published studies has found. The study, “The Role of Mycophenolate…
The disease-causing autoantibodies are sometimes present long before the onset of ANCA-associated vasculitis (AAV) symptoms, with distinct disease features depending on their antibody type, a recent study finds. Overall, the study presents “evidence of an initiation of the autoimmune process in…
Levels of the chitinase-3-like 1 (YKL-40) protein in the blood may serve as a helpful biomarker of disease activity in people with ANCA-associated vasculitis (AAV), findings from a new study suggest. Yet, additional studies are needed to validate the results and elucidate the role of YKL-40 in AAV, the…
“You are about to enter another dimension. A dimension not only of sight and sound, but of mind. A journey into a not-so-wondrous land of side effects. … Next stop: the ‘predni-zone.'” I have been living in the “predni-zone” for more than 14 years. In eosinophilic granulomatosis with polyangiitis…
Recent Posts
- Grieving the loss of retirement after going out on disability
- New model may help identify which AAV patients are at risk of blood clots
- Hidden immune activity can occur despite disease remission in AAV
- Acceptance is an ongoing practice in life with chronic illness
- Survival rate on kidney dialysis similar for those with, without AAV